CN118834840A - 嵌合痘病毒组合物及其用途 - Google Patents

嵌合痘病毒组合物及其用途 Download PDF

Info

Publication number
CN118834840A
CN118834840A CN202410528486.XA CN202410528486A CN118834840A CN 118834840 A CN118834840 A CN 118834840A CN 202410528486 A CN202410528486 A CN 202410528486A CN 118834840 A CN118834840 A CN 118834840A
Authority
CN
China
Prior art keywords
nucleic acid
virus strain
vaccinia virus
acid sequence
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202410528486.XA
Other languages
English (en)
Chinese (zh)
Inventor
Y·方
N·陈
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
City of Hope
Original Assignee
City of Hope
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by City of Hope filed Critical City of Hope
Publication of CN118834840A publication Critical patent/CN118834840A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/275—Poxviridae, e.g. avipoxvirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24121—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24132—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24151—Methods of production or purification of viral material

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Toxicology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CN202410528486.XA 2016-08-09 2017-08-09 嵌合痘病毒组合物及其用途 Pending CN118834840A (zh)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201662372408P 2016-08-09 2016-08-09
US62/372,408 2016-08-09
US201762519010P 2017-06-13 2017-06-13
US62/519,010 2017-06-13
CN201780062335.8A CN110199018B (zh) 2016-08-09 2017-08-09 嵌合痘病毒组合物及其用途
PCT/US2017/046163 WO2018031694A1 (en) 2016-08-09 2017-08-09 Chimeric poxvirus compositions and uses thereof

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201780062335.8A Division CN110199018B (zh) 2016-08-09 2017-08-09 嵌合痘病毒组合物及其用途

Publications (1)

Publication Number Publication Date
CN118834840A true CN118834840A (zh) 2024-10-25

Family

ID=61163330

Family Applications (3)

Application Number Title Priority Date Filing Date
CN202410528486.XA Pending CN118834840A (zh) 2016-08-09 2017-08-09 嵌合痘病毒组合物及其用途
CN201780062335.8A Active CN110199018B (zh) 2016-08-09 2017-08-09 嵌合痘病毒组合物及其用途
CN202410528631.4A Pending CN118853594A (zh) 2016-08-09 2017-08-09 嵌合痘病毒组合物及其用途

Family Applications After (2)

Application Number Title Priority Date Filing Date
CN201780062335.8A Active CN110199018B (zh) 2016-08-09 2017-08-09 嵌合痘病毒组合物及其用途
CN202410528631.4A Pending CN118853594A (zh) 2016-08-09 2017-08-09 嵌合痘病毒组合物及其用途

Country Status (10)

Country Link
US (2) US12084687B2 (enExample)
EP (1) EP3497209A4 (enExample)
JP (4) JP7023929B2 (enExample)
KR (3) KR20250067190A (enExample)
CN (3) CN118834840A (enExample)
AU (3) AU2017311380A1 (enExample)
CA (1) CA3033512A1 (enExample)
MX (1) MX2019001672A (enExample)
RU (2) RU2021128158A (enExample)
WO (1) WO2018031694A1 (enExample)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2934532B1 (en) 2012-12-20 2019-10-23 Purdue Research Foundation Chimeric antigen receptor-expressing t cells as anti-cancer therapeutics
EP4122492A1 (en) 2015-02-25 2023-01-25 Memorial Sloan Kettering Cancer Center Use of inactivated nonreplicating modified vaccinia virus ankara (mva)as monoimmunotherapy or in combination with immune checkpoint blocking agents for solid tumors
KR20180006916A (ko) 2015-04-17 2018-01-19 메모리얼 슬로안-케터링 캔서 센터 고형 종양에 대한 면역치료제로서 mva 또는 mva델타e3l의 용도
WO2017147554A2 (en) 2016-02-25 2017-08-31 Memorial Sloan-Kettering Cancer Center Recombinant mva or mvadele3l expressing human flt3l and use thereof as immuno-therapeutic agents against solid tumors
CN109152815B (zh) 2016-02-25 2022-10-18 纪念斯隆凯特琳癌症中心 用于癌症免疫治疗的具有胸苷激酶缺失和具有或不具有人flt3l或gm-csf表达的复制型减毒痘苗病毒
CA3019835A1 (en) 2016-04-08 2017-10-12 Purdue Research Foundation Methods and compositions for car t cell therapy
KR20250067190A (ko) * 2016-08-09 2025-05-14 시티 오브 호프 키메라 폭스바이러스 조성물 및 이의 용도
CN110582288B (zh) 2017-02-28 2024-09-20 恩多塞特公司 用于car t细胞疗法的组合物和方法
CN111107872A (zh) 2017-05-12 2020-05-05 纪念斯隆-凯特林癌症中心 有用于癌症免疫疗法的牛痘病毒突变体
CN111163803B (zh) 2017-08-11 2025-05-09 希望之城公司 表达car t细胞靶物的溶瘤病毒及其用途
WO2019144095A1 (en) 2018-01-22 2019-07-25 Seattle Children's Hospital (dba Seattle Children's Research Institute) Methods of use for car t cells
JP7568224B2 (ja) 2018-02-23 2024-10-16 エンドサイト・インコーポレイテッド Ｃａｒ ｔ細胞療法のための配列決定法
CA3093093A1 (en) * 2018-03-07 2019-09-12 Transgene Parapoxvirus vectors
WO2019213173A1 (en) * 2018-04-30 2019-11-07 City Of Hope Neural stem cell compositions including chimeric poxviruses for cancer treatment
CA3112654A1 (en) 2018-09-15 2020-03-19 Memorial Sloan Kettering Cancer Center Recombinant poxviruses for cancer immunotherapy
CN113583977B (zh) * 2020-04-30 2025-06-06 杭州康万达医药科技有限公司 可受微小rna调控的分离的重组溶瘤痘病毒及其应用
GB2614309A (en) 2021-12-24 2023-07-05 Stratosvir Ltd Improved vaccinia virus vectors
WO2023213763A1 (en) * 2022-05-02 2023-11-09 Transgene Poxvirus encoding a binding agent comprising an anti- pd-l1 sdab
KR20250052416A (ko) 2022-08-18 2025-04-18 트랜스진 키메라 폭스바이러스
WO2024245722A2 (en) * 2023-05-26 2024-12-05 Probiogen Ag Rapid selection system for the generation of recombinant enveloped viruses
US12698512B2 (en) 2023-11-06 2026-08-04 City Of Hope Methods comprising oncolytic viruses expressing CD19T and bispecific T cell engagers
WO2025184411A1 (en) 2024-02-27 2025-09-04 Calidi Biotherapeutics (Nevada), Inc. Serum-resistant eev viruses and uses thereof
WO2026107113A1 (en) 2024-11-12 2026-05-21 Calidi Biotherapeutics (Nevada), Inc. MODIFIED CELLS FOR PROGRAMMING EXTRA ENVELOPED VIRUSES (EEVs) AND THEIR USE FOR PRODUCING THE EEVs, THE PROGRAMMED EEVs AND USES THEREOF
CN120718864B (zh) * 2025-08-28 2025-11-28 山东农业大学 一种高度不成熟鸭坦布苏病毒及其培养方法和应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT406376B (de) 1998-01-16 2000-04-25 Immuno Ag Chimäres poxvirus enthaltend eine retrovirale vektorkomponente
JP2003528605A (ja) 2000-03-28 2003-09-30 ユニヴァーシティー オヴ ロチェスター ライブラリーを作成する方法および目的のポリヌクレオチドを選択する方法
ATE365220T1 (de) * 2002-11-25 2007-07-15 Bavarian Nordic As Mindestens zwei ati promotoren enthaltendes rekombinantes pockenvirus
MXPA05013879A (es) * 2003-06-18 2006-06-27 Genelux Corp Virus de la vaccinia recombinantes modificados y otros microorganismos, y usos de los mismos.
EP2415783B1 (en) * 2006-10-16 2016-12-14 Genelux Corporation Modified vaccinia virus strains for use in a diagnostic and therapeutic method
EP2212423B1 (en) * 2007-11-19 2015-02-11 Transgene SA Poxviral oncolytic vectors
JP5652830B2 (ja) 2010-04-09 2015-01-14 国立大学法人 東京大学 マイクロｒｎａ制御組換えワクシニアウイルス及びその使用
EP2697368B1 (en) 2011-04-15 2019-06-05 Genelux Corporation Clonal strains of attenuated vaccinia viruses and methods of use thereof
NZ701949A (en) * 2012-05-18 2016-07-29 Otago Innovation Ltd Combination treatments and compositions for wound healing
WO2015103438A2 (en) * 2014-01-02 2015-07-09 Genelux Corporation Oncolytic virus adjunct therapy with agents that increase virus infectivity
KR20250067190A (ko) * 2016-08-09 2025-05-14 시티 오브 호프 키메라 폭스바이러스 조성물 및 이의 용도

Also Published As

Publication number Publication date
KR20250067190A (ko) 2025-05-14
EP3497209A1 (en) 2019-06-19
KR102557818B1 (ko) 2023-07-20
KR20190038626A (ko) 2019-04-08
RU2757002C2 (ru) 2021-10-08
RU2021128158A (ru) 2022-04-07
JP2019524131A (ja) 2019-09-05
CN118853594A (zh) 2024-10-29
CN110199018A (zh) 2019-09-03
US20190218522A1 (en) 2019-07-18
JP7395628B2 (ja) 2023-12-11
MX2019001672A (es) 2019-06-06
RU2019106319A3 (enExample) 2021-03-17
JP2025072482A (ja) 2025-05-09
JP2022065034A (ja) 2022-04-26
AU2026203424A1 (en) 2026-05-21
WO2018031694A1 (en) 2018-02-15
JP2024026191A (ja) 2024-02-28
US20250084384A1 (en) 2025-03-13
CN110199018B (zh) 2024-06-07
AU2023270200B2 (en) 2026-02-05
AU2017311380A1 (en) 2019-03-28
JP7023929B2 (ja) 2022-02-22
JP7631485B2 (ja) 2025-02-18
AU2023270200A1 (en) 2024-01-25
US12084687B2 (en) 2024-09-10
BR112019002646A2 (pt) 2019-10-08
EP3497209A4 (en) 2020-07-29
CA3033512A1 (en) 2018-02-15
KR20230113832A (ko) 2023-08-01
RU2019106319A (ru) 2020-09-17

Similar Documents

Publication Publication Date Title
JP7631485B2 (ja) キメラポックスウイルス組成物及びその使用
US12161714B2 (en) Use of endogenous viral vaccine in chimeric antigen receptor T cell therapy
US10590205B2 (en) Chimeric antigen receptor compositions
US11279752B2 (en) Tumor-selective CTLA-4 antagonists
JP2025081512A (ja) 血液がんおよび固形がんの治療のためのキメラ抗原受容体改変ｔ細胞（ｃａｒ－ｔ）
US20240117047A1 (en) Monoclonal antibodies specific for human ror1
CN115916226A (zh) 用于治疗癌症的溶瘤病毒组合物和方法
US20210052660A1 (en) Neural stem cell compositions including chimeric poxviruses for cancer treatment
US20250186520A1 (en) Oncolytic virus compositions and methods for the treatment of cancer
US12617845B2 (en) SMC1A antibodies and uses thereof
US20250049866A1 (en) Cancer immunotherapy using virus particles
US20240091364A1 (en) Cancer combination treatments using anti-stat3 nucleic acid conjugates
BR112019002646B1 (pt) Composições de poxvírus quimérico e usos das mesmas

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination